-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the international investment bank Torreya released the 2021 "Report on the World's Top Thousand Pharmaceutical Companies".
There are 249 pharmaceutical companies in China on the list.
Among them, the finalists are China Hengrui Pharmaceuticals, CSPC, Qilu Pharmaceuticals, Yangzijiang Pharmaceuticals, and Pien Tze Huang.
Pharmaceutical companies have outstanding performance, ranking 24, 25, 26, 28, and 33 respectively
.
Hengrui Pharmaceuticals Hengrui Pharmaceuticals is trying to get rid of the impact of price cuts in the centralized procurement of generic drugs
.
What the company is doing is transforming from generic drugs to innovative drugs, and now the proportion of innovative drugs is increasing year by year
.
As a pharmaceutical research and development company, Hengrui Pharmaceuticals has taken technological innovation as a development strategy for many years.
In the first three quarters of 2021, it has invested a total of 4.
142 billion yuan in research and development funds, accounting for 20.
5% of operating income
.
At the same time, in recent years, Hengrui Pharmaceuticals has vigorously implemented its internationalization strategy and continuously increased its investment in internationalization.
In the first half of this year, overseas R&D expenditures were 643 million yuan, and the pace of building an international clinical R&D team and deploying international clinical trials of innovative drugs has been accelerating.
.
A number of brokerage research reports believe that as Hengrui Pharmaceuticals continues to increase its international layout, it is expected to further expand the pipeline of innovative products and increase the company's performance in the future
.
It is reported that Hengrui Medicine currently has 24 overseas research projects under development, 10 overseas research projects are planned, 7 phase III international multi-center research projects, and 12 phase I overseas research projects
.
Sinopharm Group Sinopharm Group entered the above-mentioned list with an annual revenue of 6.
5 billion U.
S.
dollars
.
CSPC continues to exert its traditional advantages in the field of central nervous system medicines
.
According to the report, CSPC is a large CNS drug distributor in China and has achieved excellent sales performance in recent years
.
It is understood that in the past ten years, CSPC has taken innovation as its strategy, R&D as the drive, industrialization as the foundation, and internationalization as the direction.
It has achieved double-digit average revenue and profit growth, and has become a domestic pharmaceutical company to transform and upgrade.
, A model of innovation and development
.
For example, according to the third quarter report data released by CSPC, the company's total revenue in the first three quarters of 2021 increased by 7.
4% year-on-year to 20.
64 billion yuan; gross profit increased by 8.
3% year-on-year to 15.
66 billion yuan
.
CSPC said that in the next five years, more than 30 innovative drugs and new preparation products, and more than 60 generic drugs are expected to be launched
.
In recent years, Qilu Pharmaceuticals, under the strategy of “emphasis on imitations and innovations”, through self-research and development, international cooperation, project introduction, university cooperation and other channels, Qilu Pharmaceutical has been able to treat urgently needed clinical tumors, autoimmune system diseases, and anti-infectives.
In the research and development of innovative drugs in other fields, the barriers have been constantly overcome, and successes have been reported frequently
.
Over the years of development, Qilu Pharmaceutical's innovative drug sector has obvious advantages, complete products of large and small molecules, and a variety of treatment methods.
Multiple overseas R&D platforms continue to inject international talents and resources.
Relying on the outstanding industrial resources of the group, the transformation of R&D results is smooth
.
According to reports, today, the company has more than 70 innovative drug research and development product lines that are simultaneously advancing, and more than 10 of them have entered the clinical stage.
It is estimated that 2 to 3 innovative drugs will be launched every year after 2022
.
Yangtze River Pharmaceuticals Yangtze River Pharmaceuticals focuses on the future of human health, and has been deeply involved in the health market for many years.
It protects health with its original intentions and creates its brand with ingenuity to drive China's health industry through waves
.
It focuses on the development of traditional Chinese medicine and health products, continues to increase investment, and deploys a large health industry from a high starting point
.
It is reported that since the beginning of the "13th Five-Year Plan" strategic transformation and upgrading, Yangzijiang Pharmaceutical has accelerated the layout of the big health industry
.
In 2013, Jiangsu Longfengtang Traditional Chinese Medicine Health Industrial Park settled in the core port area of Taizhou Port.
As of March 2017, all of its five production workshops have passed GMP certification and put into production, and Longfengtang has entered the first echelon of national intelligent manufacturing
.
At present, the National Development and Reform Commission's public service platform for quality and safety of traditional Chinese medicine and the whole process traceability, and the Ministry of Industry and Information Technology's traditional Chinese medicine process manufacturing standardization and new model application have successively settled in Longfengtang Traditional Chinese Medicine Health of Yangzijiang Pharmaceutical Group.
Industrial park
.
Pien Tze Huang Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
is a national technological innovation demonstration enterprise focusing on pharmaceutical manufacturing and research and development, with a current market value of over 150 billion
.
It has 1 research institute, 35 holding subsidiaries, 7 shareholding companies, operating 6 major categories, more than 470 product series, and establishing 23 scientific research, production and medicinal materials bases in 7 provinces and municipalities across the country
.
In the first three quarters of 021, Pien Tze Huang realized revenue increased by 20.
55% year-on-year to 6.
112 billion yuan; total profit increased by 52.
67% year-on-year to 2.
433 billion yuan; net profit increased by 52.
34% year-on-year to 2.
061 billion yuan
.
It is understood
.
In recent years, Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
has actively implemented the national strategy of "Healthy China", inherited the essence, maintained integrity and innovation, implemented the "one core and two wings" big health industry development strategy, and promoted the modernization, industrialization and internationalization of Pien Tze Huang.
In the course of high-quality development, we are constantly reaching new heights
.
There are 249 pharmaceutical companies in China on the list.
Among them, the finalists are China Hengrui Pharmaceuticals, CSPC, Qilu Pharmaceuticals, Yangzijiang Pharmaceuticals, and Pien Tze Huang.
Pharmaceutical companies have outstanding performance, ranking 24, 25, 26, 28, and 33 respectively
.
Hengrui Pharmaceuticals Hengrui Pharmaceuticals is trying to get rid of the impact of price cuts in the centralized procurement of generic drugs
.
What the company is doing is transforming from generic drugs to innovative drugs, and now the proportion of innovative drugs is increasing year by year
.
As a pharmaceutical research and development company, Hengrui Pharmaceuticals has taken technological innovation as a development strategy for many years.
In the first three quarters of 2021, it has invested a total of 4.
142 billion yuan in research and development funds, accounting for 20.
5% of operating income
.
At the same time, in recent years, Hengrui Pharmaceuticals has vigorously implemented its internationalization strategy and continuously increased its investment in internationalization.
In the first half of this year, overseas R&D expenditures were 643 million yuan, and the pace of building an international clinical R&D team and deploying international clinical trials of innovative drugs has been accelerating.
.
A number of brokerage research reports believe that as Hengrui Pharmaceuticals continues to increase its international layout, it is expected to further expand the pipeline of innovative products and increase the company's performance in the future
.
It is reported that Hengrui Medicine currently has 24 overseas research projects under development, 10 overseas research projects are planned, 7 phase III international multi-center research projects, and 12 phase I overseas research projects
.
Sinopharm Group Sinopharm Group entered the above-mentioned list with an annual revenue of 6.
5 billion U.
S.
dollars
.
CSPC continues to exert its traditional advantages in the field of central nervous system medicines
.
According to the report, CSPC is a large CNS drug distributor in China and has achieved excellent sales performance in recent years
.
It is understood that in the past ten years, CSPC has taken innovation as its strategy, R&D as the drive, industrialization as the foundation, and internationalization as the direction.
It has achieved double-digit average revenue and profit growth, and has become a domestic pharmaceutical company to transform and upgrade.
, A model of innovation and development
.
For example, according to the third quarter report data released by CSPC, the company's total revenue in the first three quarters of 2021 increased by 7.
4% year-on-year to 20.
64 billion yuan; gross profit increased by 8.
3% year-on-year to 15.
66 billion yuan
.
CSPC said that in the next five years, more than 30 innovative drugs and new preparation products, and more than 60 generic drugs are expected to be launched
.
In recent years, Qilu Pharmaceuticals, under the strategy of “emphasis on imitations and innovations”, through self-research and development, international cooperation, project introduction, university cooperation and other channels, Qilu Pharmaceutical has been able to treat urgently needed clinical tumors, autoimmune system diseases, and anti-infectives.
In the research and development of innovative drugs in other fields, the barriers have been constantly overcome, and successes have been reported frequently
.
Over the years of development, Qilu Pharmaceutical's innovative drug sector has obvious advantages, complete products of large and small molecules, and a variety of treatment methods.
Multiple overseas R&D platforms continue to inject international talents and resources.
Relying on the outstanding industrial resources of the group, the transformation of R&D results is smooth
.
According to reports, today, the company has more than 70 innovative drug research and development product lines that are simultaneously advancing, and more than 10 of them have entered the clinical stage.
It is estimated that 2 to 3 innovative drugs will be launched every year after 2022
.
Yangtze River Pharmaceuticals Yangtze River Pharmaceuticals focuses on the future of human health, and has been deeply involved in the health market for many years.
It protects health with its original intentions and creates its brand with ingenuity to drive China's health industry through waves
.
It focuses on the development of traditional Chinese medicine and health products, continues to increase investment, and deploys a large health industry from a high starting point
.
It is reported that since the beginning of the "13th Five-Year Plan" strategic transformation and upgrading, Yangzijiang Pharmaceutical has accelerated the layout of the big health industry
.
In 2013, Jiangsu Longfengtang Traditional Chinese Medicine Health Industrial Park settled in the core port area of Taizhou Port.
As of March 2017, all of its five production workshops have passed GMP certification and put into production, and Longfengtang has entered the first echelon of national intelligent manufacturing
.
At present, the National Development and Reform Commission's public service platform for quality and safety of traditional Chinese medicine and the whole process traceability, and the Ministry of Industry and Information Technology's traditional Chinese medicine process manufacturing standardization and new model application have successively settled in Longfengtang Traditional Chinese Medicine Health of Yangzijiang Pharmaceutical Group.
Industrial park
.
Pien Tze Huang Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
is a national technological innovation demonstration enterprise focusing on pharmaceutical manufacturing and research and development, with a current market value of over 150 billion
.
It has 1 research institute, 35 holding subsidiaries, 7 shareholding companies, operating 6 major categories, more than 470 product series, and establishing 23 scientific research, production and medicinal materials bases in 7 provinces and municipalities across the country
.
In the first three quarters of 021, Pien Tze Huang realized revenue increased by 20.
55% year-on-year to 6.
112 billion yuan; total profit increased by 52.
67% year-on-year to 2.
433 billion yuan; net profit increased by 52.
34% year-on-year to 2.
061 billion yuan
.
It is understood
.
In recent years, Zhangzhou Pien Tze Huang Pharmaceutical Co.
, Ltd.
has actively implemented the national strategy of "Healthy China", inherited the essence, maintained integrity and innovation, implemented the "one core and two wings" big health industry development strategy, and promoted the modernization, industrialization and internationalization of Pien Tze Huang.
In the course of high-quality development, we are constantly reaching new heights
.
